Change In Director’s Interest Notice

Dec 9, 2019
Posted in: Investor updates

Home » Change In Director’s Interest Notice

Change In Director’s Interest Notice

Dec 9, 2019
Posted in: Investor updates

Imagion Biosystems has released Change of Director’s Interest Notices for David Ludvigson, Mark Van Asten, and Robert Proulx.
Read the Change in Director’s Interest Notices:

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

September 9, 2025

Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer

Dr. Nina Webster Joins IBX Board of Directors

September 1, 2025

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging

Imagion Initiates Collaboration with Wayne State University to Develop Advanced Molecular Imaging Capabilities to Enable AI Cancer Diagnostics

August 13, 2025

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Change In Director’s Interest Notice

Change In Director’s Interest Notice

Related Articles

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Dr. Nina Webster Joins IBX Board of Directors

Imagion Initiates Collaboration with Wayne State University to Develop Advanced Molecular Imaging Capabilities to Enable AI Cancer Diagnostics

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list